Kautzky, A.
Vanicek, T.
Philippe, C.
Kranz, G. S. http://orcid.org/0000-0002-3892-1804
Wadsak, W. http://orcid.org/0000-0003-4479-8053
Mitterhauser, M.
Hartmann, A.
Hahn, A. http://orcid.org/0000-0001-9727-7580
Hacker, M.
Rujescu, D.
Kasper, S.
Lanzenberger, R. http://orcid.org/0000-0003-4641-9539
Article History
Received: 23 October 2019
Revised: 20 February 2020
Accepted: 28 February 2020
First Online: 7 April 2020
Conflict of interest
: S.K. received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe and Servier. R.L. received conference speaker honorarium within the last three years from Shire and support from Siemens Healthcare regarding clinical research using PET/MR, and is shareholder of BM Health GmbH since 2019. W.W. received speaker honoraria from GE Healthcare, research grants from DSD, BSM Diagnostica and ABX and is a part time employee of CBmed GmbH (Graz, Austria). M. Mitterhauser received speaker honoraria from GE Healthcare, research grants from DSD, BSM Diagnostica, BAYER and ABX and is a part time employee of CBmed GmbH (Graz, Austria). G.S.K. received travel grants from Roche and Pfizer. The other authors report no potential conflict of interest with relevance to this work.